In diabetic rodents and humans, glucose transporter 4 (GLUT4) expression is suppressed in adipocytes in association with insulin resistance. Transgenic mice overexpressing GLUT4 selectively in fat have enhanced glucose disposal in vivo and massively increased glucose transport in adipocytes. To determine whether overexpression can be maintained in diabetes and whether it can prevent insulin resistance, we rendered wild-type and transgenic mice diabetic with streptozotocin. After 12-14 days, blood glucose was more than 21.4 mM and plasma insulin was 1.06 ng/ml or less in both diabetic groups in the fed state. Body weight was reduced and gonadal fat pad weight and adipocyte size were 52-75% smaller in both nontransgenic and transgenic diabetic mice, compared with nondiabetic. Basal and maximally-stimulated rates of lipolysis were similar in adipocytes from nontransgenic and transgenic mice, but the ED 50 for isoproterenol stimulation was 50% lower in transgenic mice. There was no difference in the sensitivity to insulin to inhibit lipolysis. In adipocytes of nontransgenic diabetic mice, GLUT4 protein was reduced 34%, with a 46% reduction in insulin stimulated glucose transport. In contrast, in adipocytes of transgenic diabetic mice, GLUT4 remained 21-fold overexpressed, resulting in 21-fold increased basal and 10-fold increased insulin stimulated glucose transport. Injection of insulin (0.7 mU/g BW) resulted in a 35% decrease in blood glucose in transgenic diabetic mice (P Ͻ 0.05), with no effect in nontransgenic diabetic mice. Thus, high-level overexpression of GLUT4 driven by a fat specific promoter can be maintained with insulinopenic diabetes, even when fat cell metabolism is markedly altered. Overexpression of GLUT4 in adipocytes prevents insulin resistant glucose transport at the cellular level and improves insulin action in vivo, even with overt diabetes.
T YPE I and Type II diabetes in humans are associated with insulin resistant glucose uptake in peripheral tissues. Even after insulin levels are restored to normal in Type I diabetics (1, 2) or increased to several times normal in Type II diabetics (3, 4) , peripheral insulin resistance persists and is central to the pathophysiology of diabetes (1) (2) (3) (4) (5) . One of the primary mechanisms of insulin resistance in these states is impaired glucose transport and metabolism in adipose cells and muscle. In adipose cells, unlike in muscle, the main cause is pretranslational suppression of the expression of the major insulin responsive glucose transporter, GLUT4 (6, 7) . In fact, the element(s) responsible for transcriptional regulation of GLUT4 expression in adipose tissue in the diabetic state have been identified and reside 2.4 kb upstream of the transcriptional initiation site (8) .
Reduced GLUT4 expression in adipocytes is virtually a universal feature of insulin resistant states resulting from somewhat diverse etiologies, including not only obesity, impaired glucose tolerance, noninsulin-dependent diabetes mellitus, polycystic ovarian disease, some cases of gestational diabetes, and high fat feeding, but also insulinopenic diabetes and fasting (9) . In contrast, in most of these states, there is no decrease in GLUT4 expression in muscle. In the few rodent models in which down-regulation of GLUT4 expression in muscle can be seen, it actually follows the onset of insulin resistance and thus is not the primary cause (10, 11) . The contribution of down-regulation of GLUT4 expression in adipocytes to total body insulin resistance is unknown.
Recent transgenic studies demonstrate that overexpression of GLUT4 in muscle and adipose tissue together (12) (13) (14) (15) (16) , in muscle alone (17, 18) , or in adipocytes alone (19) enhances glucose tolerance and insulin-stimulated glucose uptake in vivo in normal mice and prevents insulin resistance (12) and ameliorates diabetes (13, 17) in mice with metabolic perturbations. Gibbs et al. (13) overexpressed GLUT4 driven by its own promoter in genetically obese, diabetic (db/db) mice and showed striking amelioration of the diabetic state. Similarly, GLUT4 overexpression simultaneously in muscle and adipose tissues in C57BL mice prevents impaired glucose tolerance that occurs in nontransgenic mice fed a high-fat diet (12) . GLUT4 overexpression selectively in muscle, using an aldolase promoter, improves the glucose lowering effect of insulin in streptozotocin diabetic transgenic mice (17) . Furthermore, Tsao et al. (18) overexpressed GLUT4 selectively in slow twitch muscle of transgenic mice using the myosin light chain promoter/enhancer and showed that glucose uptake in vivo is enhanced only in the muscles in which the transgene is expressed. This indicates that the effects of GLUT4 on glucose homeostasis are direct and are not, for the most part, the result of changes in circulating levels of hormones or substrates.
Because GLUT4 down-regulation in insulin-resistant states is most pronounced in adipocytes and there is no information as to whether the decreased glucose uptake into fat contributes to in vivo insulin resistance, we sought to prevent down-regulation of GLUT4 selectively in adipocytes and to study the impact in diabetic mice. Our specific questions were: 1) Can GLUT4 expression be maintained in adipocytes in a diabetic state in which it is usually down-regulated, if it is driven by a heterologous promoter that may not be subject to down-regulation in adipocytes, as the endogenous promoter is? 2) If GLUT4 expression can be maintained, or even increased above normal levels in adipocytes in the diabetic state, will insulin action in vivo improve? 3) Will overexpression of GLUT4 in adipose tissue ameliorate the catabolic/lipolytic state associated with insulinopenic diabetes? To answer these questions, we created diabetes in mice that overexpress GLUT4 driven by the aP2, fatty acidbinding protein, promoter/enhancer (19) . We found that GLUT4 expression driven by this heterologous promoter can be maintained at high levels under conditions where the endogenous promoter normally down-regulates and that this sustains enhanced glucose transport in isolated adipocytes. Furthermore, overexpression of GLUT4 selectively in adipocytes improves whole-body insulin action, even with severe diabetes. These results are consistent with the interpretation that down-regulation of GLUT4 in adipocytes may contribute, either directly or indirectly, to in vivo insulin resistance in diabetes.
Materials and Methods

Transgenic mice
Mice were created, as previously described (19) , by injection of a transgene consisting of 5.4 kb of the adipose-specific promoter/enhancer (gift of B. M. Spiegelman and R. Graves) of the fatty acid-binding protein gene aP2 (20) , ligated to a 6.3-kb BamH1-PvuII genomic DNA fragment corresponding to bases 2061-8396 of the human GLUT4 gene (gift of J. Buse and G. I. Bell) (21) . Mice were genotyped by Southern blotting or PCR using primers previously described (22) . Mice were housed at 21 C with a 12-h light/dark cycle and were fed standard Purina mouse chow no. 5008 ad libitum. After a 6-h fast, heterozygous male or female mice and nontransgenic littermates 12-16 weeks old were injected ip with streptozotocin, 170 -180 mg/kg BW. Control mice were injected with an equal volume of saline. Body weights and blood glucoses were monitored every 2 days after injection. Insulin tolerance tests were carried out 12 days later in representative diabetic mice. Twelve to 14 days after streptozotocin injection, mice were killed for in vitro studies. All studies were approved by the Beth Israel Hospital Animal Care and Use committee. Studies were conducted in accord with the principles and procedures outlined in the NIH Guide for the Care and Use of Laboratory Animals. 
Blood glucose and plasma insulin determinations
Glucose transport in isolated adipose cells
Adipose cells were isolated from gonadal fat pads of 1-5 mice per experiment by collagenase digestion (1 mg/ml). Cells were incubated at 37 C with constant shaking in a 4% suspension by volume (ϳ40,000 cells/500 l), in Krebs-Ringer-Phosphate buffer (pH 7.4) with HEPES (20 mm), 2.5% BSA (fraction V), and 200 nm adenosine. Cells were incubated in the absence (basal) or presence of 80 nm crystalline porcine insulin (insulin stimulated) (gift of Eli Lilly, Indianapolis, IN) for 30 min. U-[
14 C] glucose (ICN Biomedical, Costa Mesa, CA) (3 m) was added for 30 min, and the reaction was terminated by separating cells from media by spinning the suspension through dinonyl phthalate oil (Kodak, New Haven, CT) (23, 24) .
At a glucose concentration of 3 m under the assay conditions used, U-14 C-glucose uptake has been shown to directly reflect glucose transport, and results parallel those with 3-O-methylglucose transport (23, 24) . We validated this technique for adipocytes from nontransgenic and transgenic mice. At a glucose concentration of 3 m, a cell concentration of 2-4% by vol and an incubation time of 30 min, this assay is linear for adipocytes from both nontransgenic and GLUT4 overexpressing mice. Furthermore, our initial comparisons of U-14 C-glucose uptake and 3-Omethylglucose transport show similar effects of the transgene with both techniques.
Lipolysis in isolated adipose cells
A 10% suspension of isolated adipose cells from 1-2 mice per group was prepared in KRPH buffer, 200 nm adenosine, 2.5% BSA, and 2 mm glucose at pH 7.4. Cells [100 l (ϳ20,000 cells)] were incubated in a final vol of 500 l with adenosine deaminase (1 unit/ml, Sigma, St. Louis, MO) and N 6 -[R-1-methyl-2-phenethyl]adenosine (10 m, Sigma) (25, 26) . Lipolysis was stimulated by isoproterenol (10 nm, 100 nm, 1 m, 10 m, and 100 m) for 15 min at 37 C with vigorous shaking. The effect of insulin in inhibiting lipolysis was measured by adding insulin at 0.25 nm, 0.5 nm, 1 nm, 10 nm, and 100 nm for 15 min at 37 C and then stimulating lipolysis with 10 m isoproterenol for 15 min at 37 C. The reactions were terminated by spinning cells through dinonyl phthalate oil. The glycerol released into the media was measured using a radiometric assay (27) . The assay was linear under the stated conditions.
Preparation of membranes and Western blotting for GLUT4
Total membranes were prepared from intact fat pads, separated by SDS-PAGE, electrophoretically transferred to nitrocellulose, and immunoblotted with an antiserum specific for the COOH terminal of GLUT4 (gift of H. Haspel), all as previously described (6, 28) . Results were quantitated by Phosphorimaging or densitometry of autoradiograms.
Adipose cell size and number
Isolated adipocytes were fixed with osmic acid and counted in a Coulter counter (Coulter Electronics Ltd., Luton, Beds, UK) (29, 30) , and cell size (g lipid/cell) was calculated as previously described (30) .
Insulin tolerance tests
After a 6-h fast, insulin (Humulin regular, Eli Lilly) was injected ip at a dose of 0.9 -1 mU/g BW for males and 0.7 mU/g BW for females in unanesthetized and unrestrained mice. Different doses were used because normal female mice were more sensitive to insulin than normal male mice. An additional group of diabetic male mice was injected with an insulin dose of 3.3 mU/g BW to determine the maximal effect of insulin. Blood glucose was sampled from the tail vein before injection and at 30, 45, and 60 min after injection.
Glucose transport in soleus muscle in vitro
3-O-methylglucose transport was performed in isolated soleus muscles as previously described for rat epitrochlearis (31) . Glucose transport is expressed as m 3-O-methylglucose accumulated per ml of intracellular water per h.
Statistical analysis
Statistical analyses were carried out with ANOVA, Fisher's test, and t test using the Statview program (Abacus Concepts Inc., Apple Computer Inc., Cupertino, CA). Differences were accepted as significant at P Ͻ 0.05. Table 1 shows blood glucose and plasma insulin levels in nondiabetic (control) and diabetic male and female mice of both genotypes. On the day of injection, blood glucoses after a 6-h fast were lower in transgenic male and female mice compared with nontransgenic mice of the same sex (P Ͻ 0.05), as we previously showed with an overnight fast (19) . Fed glucoses on the day the mice were killed were not different between genotypes for nondiabetic mice. After streptozotocin injection, mice of both genotypes and both sexes became diabetic, with blood glucoses more than 24.7 mm in males and more than 21.4 mm in females of both genotypes on the day they were killed (12-14 days after injection). Fed insulin levels in nondiabetic mice were significantly lower in transgenic males compared with nontransgenic males (P Ͻ 0.05) (19) . Insulin levels also tended to be lower in nondiabetic transgenic females (P Ͻ 0.06). Insulin levels were reduced to the same degree in both nontransgenic and transgenic mice after streptozotocin injection (0.71-0.73 ng/ml in males of both genotypes and 1.00 -1.06 ng/ml in females). Figure 1A shows the effect of the diabetic state on body weight in nontransgenic and transgenic mice. Nondiabetic mice of both genotypes and both sexes gained a small amount of weight, whereas diabetic mice of both genotypes and both sexes lost weight. The amount of weight gained or lost was not statistically different between genotypes for either males or females. Thus, overexpression of the transgene did not prevent weight loss. The relatively small weight gain in nondiabetic mice over 12-14 days is in contrast to results in rats. However, it is a consistent finding in our strain of mice that weight gain is slow after the age of 12 weeks.
Results
Characteristics of the mice
Effects of diabetes on adiposity
Parallel changes were seen with fat pad weight (Fig. 1B) . In nondiabetic mice, gonadal fat pad weight was 44% (male) and 42% (female) greater in transgenic than nontransgenic mice at the time of death (P Ͻ 0.002). Diabetes resulted in a 72% (male) and 42% (female) reduction in fat pad weight in nontransgenic mice and a 77% (male) and 58% (female) reduction in transgenic mice. Figure 1C shows that adipose cell size was similar in nondiabetic nontransgenic and transgenic mice, confirming our previous reports (19) . With diabetes, adipose cell size in both genotypes and both sexes decreased: 56% in nontransgenic male, 75% in transgenic male, 44% in nontransgenic female, and 52% in transgenic female mice. Thus, overexpression of GLUT4 did not protect adipocyte size or adipose mass. Figure 2 shows the effects of diabetes on the regulation of GLUT4 protein levels in adipose tissue. Panel A shows a representative Western blot, which indicates that GLUT4 expression decreases in nontransgenic diabetic mice and that GLUT4 is markedly overexpressed in both nondiabetic and diabetic transgenic mice. Panel B shows the quantitation by phosphorimaging. In nontransgenic mice, streptozotocin diabetes results in a 34% reduction in GLUT4 levels in adipose tissue (P Ͻ 0.001). In nondiabetic transgenic mice, GLUT4 is overexpressed 18-fold compared with nontransgenic nondiabetic mice. With diabetes, GLUT4 levels in adipose tissue of transgenic mice do not decrease significantly (P ϭ 0.46) and remain 21-fold greater than in adipose tissue from diabetic nontransgenic mice. Figure 3 shows the effects of diabetes and GLUT4 overexpression on glucose transport in adipocytes. In nontransgenic mice, insulin stimulates glucose transport approximately 5-fold (P Ͻ 0.0001). Diabetes results in no significant change in basal glucose transport but a 46% decrease in 
Effects of diabetes on GLUT4 expression and glucose transport in adipocytes
Values are means Ϯ SE. a On the injection day, blood glucose was measured after a 6-h fast in nondiabetic mice who were designated either to receive streptozotocin injection (diabetic) or saline injection (control). On the day of killing, blood glucose and plasma insulin were measured at 0930 -1030 h after ad libitum feeding. The number of mice in each group is indicated in parentheses. For control mice, n is sometimes lower on the injection day than on the day they were killed because not all the control animals were monitored for blood glucose on the injection day. On the other hand, in the diabetic group, n is lower on the death day compared with the injection day because several animals died before the day scheduled for killing.
b Significant difference from nontransgenic control at P Ͻ 0.05. c Significant difference from transgenic control at P Ͻ 0.001.
insulin stimulated glucose transport, compared with nontransgenic nondiabetic mice (P Ͻ 0.02). Overexpression of the transgene in nondiabetic mice results in a 17-fold increase in basal transport (P Ͻ 0.0001) and a 7-fold increase in insulin stimulated transport (P Ͻ 0.0001), as we previously reported (19) . Although the fold response to insulin (insulin-stimulated divided by basal transport) is reduced in adipocytes from transgenic mice because of the high basal transport, the increment in attomoles of glucose transported per cell (insulin stimulated minus basal) is four times greater in transgenic cells, indicating that the GLUT4 overexpressing-cells are very responsive to insulin. Even with diabetes, dramatic increases in glucose transport are maintained in cells from transgenic mice. Although there is a tendency for a slight reduction in insulin-stimulated glucose transport in diabetic transgenic mice compared with nondiabetic transgenic mice, this is not statistically significant. Most importantly, when comparing values in diabetic mice directly, basal transport is increased 21-fold (P Ͻ 0.0001) and insulin stimulated-transport, 10-fold (P Ͻ 0.0001) in cells from transgenic diabetic mice, compared with nontransgenic diabetic mice. The transport data shown are for females. Overexpression of GLUT4 in adipocytes of male mice had a similar effect, maintaining markedly increased glucose transport, even in the setting of diabetes (not shown). In adipocytes from nontransgenic male mice, streptozotocin diabetes was associated with a 60% decrease in insulin-stimulated glucose transport, compared with nondiabetic mice. With GLUT4 overexpression, insulinstimulated glucose transport was 6.5-fold higher in male
FIG. 1. Effects of streptozotocin-diabetes on body weight (A), fat pad mass (B)
, and fat cell size (C) in nontransgenic and transgenic mice. Panel A, Mice were weighed on the injection and the sacrifice days and body weight gain or loss during the treatment period (12-14 days) was calculated in grams for each mouse. Panel B, On the day the mice were killed, perigonadal fat pads from nontransgenic and transgenic, control (nondiabetic) and diabetic (stz) mice were weighed. For panels A and B, results are means Ϯ SE for 9 -25 males and 13-32 females per group. Panel C, Adipocytes were isolated from perigonadal fat pads of nontransgenic or transgenic, control, and diabetic (stz) mice, and cell size was measured in cells pooled from 1-5 mice per group as described in Materials and Methods. Values are the means Ϯ SE of 6 -12 experiments per group. *, Significant difference from nondiabetic control of the same genotype and sex at P Ͻ 0.001; ϩ , significant difference between nontransgenic and transgenic control at P Ͻ 0.01; stz, streptozotocin injected mice. diabetic transgenic mice, compared with male diabetic nontransgenic mice (P Ͻ 0.0025). Figure 4A shows dose response curves for stimulation of lipolysis by the ␤ adrenergic agonist, isoproterenol. Basal and maximal rates of lipolysis were similar in adipocytes from nontransgenic and transgenic mice. The ED 50 for stimulation was reduced by 50% in transgenic adipocytes (P Ͻ 0.027), indicating slightly increased sensitivity to ␤ adrenergic stimulation. The effect is too small to see on the log plot and is shown in the bar graph inset.
Effects of GLUT4 overexpression in adipocytes on lipolysis
The effect of insulin (to inhibit lipolysis) was measured over a range of insulin concentrations (Fig. 4B) encompassing the plasma insulin concentrations in mice in this study (Table  1) . Although there was a tendency for a slightly diminished effect of insulin to inhibit lipolysis at all insulin concentrations, this did not reach statistical significance for any one concentration. Concentrations of 0.5-1.0 nm correspond to the plasma insulin concentrations in the nondiabetic mice of both genotypes and 0.12-0.2 nm, to the concentrations in diabetic mice. Figure 5 shows the results of insulin tolerance tests in awake, unrestrained diabetic mice of both genotypes. Initial blood glucose, after a 6-h fast, was 21.9 Ϯ 0.5 mmol/l in nontransgenic and 22.7 Ϯ 0.9 mmol/l in transgenic female mice. When 0.7 mU insulin per gm BW was injected into nontransgenic diabetic female mice, there was no significant change in blood glucose (Fig. 5) . In contrast, in transgenic diabetic female mice, blood glucose fell to a level significantly lower than initial values and than nontransgenic diabetic values at 30, 45, and 60 min after insulin injection (P Ͻ 0.05). Studies also were carried out in male mice using higher insulin doses (0.9 -1.0 mU/g). Blood glucose fell in both nontransgenic and transgenic males; however, the effect was greater in transgenics. Blood glucose fell by 60 Ϯ 7% at 60 min after insulin injection in transgenic diabetic males, compared with 42 Ϯ 5% in nontransgenic diabetic males (P Ͻ 0.05, n ϭ 5-15 per group). When much higher doses of insulin were injected (3.3 mU per gm BW), blood glucose fell rapidly in nontransgenic diabetic mice also (25.4 Ϯ 0.76 mm before insulin and 7.79 Ϯ 0.77 at 30 min after insulin; not shown). Because the ameliorative effect of GLUT4 overexpression is apparent at submaximal insulin concentrations and a high dose of insulin rapidly lowers blood glucose also in nontransgenic diabetic mice, it seems that adipose-specific GLUT4 overexpression increases insulin sensitivity.
Effects of GLUT4 overexpression in adipocytes of diabetic mice on insulin responsiveness in vivo
Glucose transport in skeletal muscle in vitro
To determine whether the differences in the whole body response to insulin could be caused by inherent changes in skeletal muscle as an indirect effect of transgene overexpression in fat, we measured glucose transport in isolated soleus muscle. 3-O-methylglucose transport in the absence of insulin tended to be slightly (27%) higher in muscle from transgenic mice, although this did not reach statistical significance (nontransgenic ϭ 3.97 Ϯ 0.39, transgenic ϭ 5.05 Ϯ 0.16 mol/ml⅐h, mean Ϯ sem, n ϭ 4 -7 per group, P ϭ not significant). There was no difference in maximally insulinstimulated glucose transport in muscle from the two genotypes (nontransgenic ϭ 10.70 Ϯ 0.88, transgenic ϭ 8.28 Ϯ 0.68, P ϭ not significant).
Discussion
Our current study demonstrates that the usual suppression of GLUT4 transcription in adipocytes from diabetic mice can be overcome by driving GLUT4 expression with a heterologous promoter. This overexpression of GLUT4 selectively in adipocytes can prevent impaired insulin-stimulated glucose transport at the cellular level and can improve whole-body insulin-stimulated glucose uptake. The ameliorative effect seems to be a consequence (direct or indirect) of an increase in both basal and insulin-stimulated glucose uptake in adipocytes from transgenic mice.
This may seem unexpected, considering that fat is thought to account for relatively little glucose use in vivo. However, in studies in which a comprehensive assessment of the pathways for adipose cell glucose metabolism was performed (including, importantly, glucose conversion to lactate), adipose tissue took up as much as 15% of an oral glucose load in normal lean humans and up to 30 -50% in obese humans (32, 33) . Additional evidence that glucose uptake into adipose tissue could play an important role in whole-body glucose homeostasis comes from studies in which overexpression of GLUT4 selectively in adipocytes of nondiabetic transgenic mice was shown to improve whole-body glucose tolerance and to lower plasma insulin levels, indicating increased insulin sensitivity (19) . The current study demonstrates that in diabetic mice, overexpression of GLUT4 in adipocytes can improve insulin sensitivity. This improvement could be caused by direct effects in fat or possibly by indirect effects on other tissues. We found no significant difference in glucose transport in skeletal muscle from nontransgenic vs. transgenic mice. Preliminary results suggest no difference in the effect of submaximal insulin to suppress hepatic glucose output in nontransgenic and transgenic mice. However, this does not preclude possible differences in glucose uptake in muscle or glucose output by liver in the intact diabetic animal, caused by differential effects of circulating substrates or counterregulatory hormones in nontransgenic and transgenic mice.
The ameliorative effects of adipose-specific GLUT4 overexpression occur, even though overexpression of GLUT4 does not reverse the catabolic state of the diabetic mice. In fact, adipose cell integrity is profoundly affected, as evidenced by a similar decrease in cell size and fat pad mass in nontransgenic and transgenic diabetic mice. This is probably caused, in large part, by accelerated lipolysis resulting from the lack of insulin and the elevation in glucagon levels, which accompany this uncontrolled diabetic state. In vitro lipolysis studies show a slight increase in sensitivity to isoproterenol in cells from GLUT4 overexpressing mice (Fig. 4A) . Furthermore, at insulin concentrations in the order of magnitude of the levels in the mice in this study, there was no enhancement of the antilipolytic effect of insulin (Fig. 4B) . Thus, increased lipolysis, driven by the uncontrolled diabetic state, most likely overrides the modest increase in lipogenesis, resulting in decreased size of adipocytes from transgenic mice, similar to that seen in nontransgenic diabetic mice. The release of free fatty acids from lipolysis could contribute to insulin resistance in other organs, such as skeletal muscle and liver, in both nontransgenic and transgenic diabetic mice.
This may, in part, explain the lack of improvement in ambient blood glucose levels in diabetic transgenic mice, when plasma insulin levels are very low, as in our study. Furthermore, although basal glucose transport in isolated adipocytes from transgenic mice is increased 20-fold when measured at tracer glucose concentrations, the increase in basal glucose uptake at physiological (5 mm) glucose concentration is only 2-to 3-fold (22) and is probably lower at the elevated glucose concentrations present in these diabetic mice. Hence, in the setting of very low plasma insulin concentrations, the effect of the transgene on glucose uptake in adipocytes may not be sufficient to overcome the insulin resistance in skeletal muscle and liver induced by the diabetic state. However, when insulin is administered, increased sensitivity is evident in the transgenic mice (Fig. 5) . Leturque et al. (17) recently showed an improved effect of insulin injection on blood glucose in streptozotocin diabetic transgenic mice in which GLUT4 overexpression was driven by a muscle-specific promoter. Even though muscle is the major tissue responsible for insulin-stimulated glucose disposal (34) in vivo, only a very small improvement in ambient blood glucose levels was seen, compared with nontransgenic diabetic littermates (17) . This occurred under experimental conditions in which both nontransgenic and transgenic mice had milder hyperglycemia and for a shorter duration of time than the mice in our study. Although the effect might be greater with higher levels of GLUT4 expression in muscle, FIG. 5 . Effects of adipose-specific GLUT4 overexpression on wholebody insulin tolerance in diabetic mice. Insulin tolerance tests were performed in awake mice after a 6-h fast. Female mice were injected with an insulin dose of 0.7 mU/g of BW. Blood glucose was significantly lower at 30, 45, and 60 min after insulin injection (P Ͻ 0.05) in transgenic diabetic mice, compared with nontransgenic diabetic mice. Results were calculated as % of the fasting blood glucose value for each mouse. Data are means Ϯ SE for four transgenic and five nontransgenic diabetic female mice. *, Difference between nontransgenic and transgenic at P Ͻ 0.05. these data underscore the fact that it is difficult to achieve a major improvement in blood glucose when insulin levels are very low. In contrast, when insulin is present, as in high-fat fed (12) or db/db (13) mice, even in the setting of marked insulin resistance, GLUT4 overexpression in muscle and fat simultaneously reduces insulin resistance (12) and results in much greater amelioration of the diabetic state (13) . Although we did not see an improvement in glucose tolerance, in adipose-specific GLUT4 overexpressing mice fed a highfat diet (35) , glucose tolerance depends partly on the ability to secrete insulin, which can be impaired by high fat feeding. Thus, it is not as direct an assessment of insulin sensitivity as the insulin tolerance tests performed in the current study. In fact, in adipose-specific GLUT4 overexpressing mice fed a high fat diet, we did observe a consistent trend toward lower ambient insulin levels, compared with nontransgenic mice on the same diet (35) , which is consistent with the notion that GLUT4 overexpression in fat reduces insulin resistance.
The improvement seen in this study in the setting of streptozotocin diabetes is somewhat surprising, considering that recent data indicate that insulin action is initiated by an elaborate cascade of signaling events (36) . Streptozotocin diabetes has been shown to result in alterations that enhance multiple steps in insulin signaling, including insulin binding in adipocytes and muscle (37) (38) (39) ; tyrosine phosphorylation of the insulin receptor, as well as nonreceptor proteins including IRS-1 (40); PI3 kinase activity immunoprecipitated by IRS-1 (41); and the amount of the 85-kDa subunit of PI3 kinase that associates with IRS-1 in response to insulin (41) . However, in spite of all these changes, insulin-stimulated glucose transport is depressed in adipocytes and muscle of streptozotocin diabetic rodents (10, 42) . Only the overexpression of GLUT4 restores or increases insulin-stimulated glucose transport at the level of the tissue in which the transgene is expressed, and this improves whole body glucose uptake in response to insulin.
Our study demonstrates that using a heterologous promoter, GLUT4 expression can be maintained at very high levels, even in a tissue where its transcription is normally suppressed by diabetes (8) . Furthermore, overexpression of GLUT4 in adipocytes improves insulin action in vivo in the setting of severe diabetes. This is consistent with the interpretation that glucose uptake into fat can play a significant role (either directly or indirectly) in the regulation of wholebody glucose homeostasis and that down-regulation of GLUT4 in adipocytes may contribute to the insulin resistance associated with diabetes. In comparison with several studies in which GLUT4 was overexpressed using its own promoter (12) (13) (14) 43) or muscle specific promoters (17, 18) , driving GLUT4 with an adipocyte-specific promoter can achieve significantly higher levels of expression in both nondiabetic and diabetic mice. Although fat alone may not be the optimal target for GLUT4 overexpression, these data indicate that certain heterologous promoters may be very useful for highlevel overexpression of GLUT4. Taken together with other recent studies (12, 13, 17) , these data indicate that GLUT4 could be an important target for development of new therapies for treating or preventing diabetes, including (potentially) gene therapy.
